Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.47 |
| ▸ | PDE4A | P27815 | 9/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157512 | 0.89 | POLB (0.51) | POLBPDE4BPDE4DPDE4AEPHX2 | |
| SCHEMBL1157617 | 0.88 | POLB (0.55) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157471 | 0.85 | POLB (0.57) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157480 | 0.84 | PDE4A (0.57) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157478 | 0.84 | POLB (0.59) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157367 | 0.84 | PDE4A (0.62) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157433 | 0.84 | POLB (0.59) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157647 | 0.83 | POLB (0.57) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157756 | 0.81 | POLB (0.55) | POLBPDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1157799 | 0.81 | POLB (0.55) | POLBPDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| EP-1353907-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002074726-A2 | ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | POLB 1326/4885PDE4B 2/4885PDE4D 9/4885 |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | POLB 1326/4885PDE4B 2/4885PDE4D 9/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | POLB 1326/4885PDE4B 2/4885PDE4D 9/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | POLB 1404/4885PDE4B 2/4885PDE4D 8/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | POLB 1404/4885PDE4B 2/4885PDE4D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.